Journal of Parasitic Diseases

, Volume 42, Issue 4, pp 616–620 | Cite as

Evaluation of the efficacy of intralesional Glucantime plus niosomal zinc sulphate in comparison with intralesional Glucantime plus cryotherapy in the treatment of acute cutaneous leishmaniasis, a randomized clinical trial

  • Saeedeh Farajzadeh
  • Rahim Ahmadi
  • Saman Mohammadi
  • Abbas Pardakhty
  • Maryam Khalili
  • Mahin AflatoonianEmail author
Original Article


Current treatment modalities in cutaneous leishmaniasis have low efficacy and high toxicity as well as high rate of resistance to treatment. In this study, for the first time we decided to evaluate efficacy of intralesional Glucantime plus niosomal zinc sulphate in comparison with intralesional Glucantime plus cryotherapy in the treatment of acute cutaneous leishmaniasis. This is a case–control study on 64 patients with cutaneous leishmaniasis in Kerman-Iran. Patients were categorized in 2 groups A and B whom were treated with weekly intralesional meglumine antimonite plus twice daily niosomal topical zinc sulphate versus weekly intralesional Glucantime plus every other week cryotherapy, respectively. We assessed the efficacy of treatment modalities (as partial and complete response) and their adverse effects by measuring size of the lesions every 2 weeks up to maximum of 12 weeks and 3 months after the end of the treatment. Partial response rate was 16.6% and 12.9% in group A and B, respectively (P = 0.784). Complete response rate was 73.3% and 80.6% in group A and B, respectively (P = 0.784). Complete response rate was achieved in 4.73 ± 0.29 weeks and 4.69 ± 0.28 weeks in group A and B, respectively (P = 0.925). Partial response rate was achieved in 2.92 ± 0.23 weeks and 2.65 ± 0.18 weeks, respectively (P = 0.365). Combination of niosomal zinc sulphate with intralesional Glucantime has equal efficacy versus combination of cryotherapy plus intralesional Glucantime in the treatment of acute cutaneous leishmaniasis. So, it can be used in cases that have resistance to first-line treatments.


Noisomes Leishmaniasis Zinc sulphate Glucantime 



This investigation was extracted from an approved MD dissertation (specialty in dermatology) written by Rahim Ahmadi and financially supported by Kerman University of Medical Sciences.

Author contributions

MA wrote the manuscript and proposal, and acted as Corresponding author. SF involved in the conception, data screening and manuscript writing. MKH helped in data interpretation, literature search and manuscript writing. SM supervised development of work, helped to evaluate and edit the manuscript. AP provided niosomal drug and contributed in manuscript writing. RA helped in data acquisition, manuscript writing. All authors contributed in initial design, data analysis, reviewed, revised, and confirmed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests

Ethical approval

In this study, ethical permission (No. IR.KMU.AH.REC.1395.6) was granted through the Science and Ethics Committee of Kerman University of Medical Silences. All performed procedures were in accordance with the ethical standards of the Iranian institutional and/or national research committee and with the standards of 1964 Helsinki declaration.


  1. Aflatoonian M, Fekri A, Rahnam Z, Khalili M, Pardakhti A, Khazaeli P, Bahadini K (2017) The efficacy of combined topical niosomal dapsone gel and intralesional injection of meglumine antimoniate in comparison with intralesional meglumine antimoniate and cryotherapy in the treatment of cutaneous leishmaniasis. J Pak Assoc Dermatol 26(4):353–360Google Scholar
  2. Al Jaser M, El-Yazigi A, Kojan M, Croft SL (1995) Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemother 39(2):516–519PubMedPubMedCentralGoogle Scholar
  3. Al-Majali O, Routh HB, Abuloham O, Bhowmik KR, Muhsen M, Hebeheba H (1997) A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 36(6):460–462PubMedGoogle Scholar
  4. Asadi M, Pardakhty A, Moshafi M, Sharifi I (2012) Preparation and in vivo administration of paromomycin niosomes in balb/c mice. Res Pharm Sci 7(5):373Google Scholar
  5. Bahamdan KA, Tallab TM, Johargi H, Nourad MM, Ibrahim K, Sherbini AH et al (1997) Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 36(1):59–60PubMedGoogle Scholar
  6. Desjeux P (2001) The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95(3):239–243PubMedGoogle Scholar
  7. Dogra J, Aneja N, Lal BB, Mishra SN (1990) Cutaneous leishmaniasis in India. Int J Dermatol 29(9):661–662PubMedGoogle Scholar
  8. Esfandiarpour I, Alavi A (2002) Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 41(8):521–524PubMedGoogle Scholar
  9. Farajzadeh S, Parizi MH, Haghdoost AA, Mohebbi A, Mohammadi S, Pardakhty A, Fekri AR (2016) Comparison between intralesional injection of zinc sulfate 2% solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial. J Parasit Dis 40(3):935–939PubMedGoogle Scholar
  10. Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, Dowlati Y (2005) Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. J Drugs Dermatol 4(1):73–79PubMedGoogle Scholar
  11. Griffiths WAD, Sodeify M (1976) Use of metronidazole in cutaneous leishmaniasis. Arch Dermatol 112(12):1791PubMedGoogle Scholar
  12. Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ (2004) Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 209(1):46–49PubMedGoogle Scholar
  13. Lerner EA, Grervelink SA (1996) Leishmaniasis. In: Ardnt KA, LeBoit PE, Robinson JK, Wintroub BU (eds) Cutaneous medicine and surgery, 1st edn. WB Saunders, Philadelphia, pp 1163–1171Google Scholar
  14. Lopez V, Hay RJ (2004) Parasitic worms and protozoa. In: Burns T, Breathnach S, Cox N, Griffiths C (eds) Rook’s textbook of dermatology, 7th edn. Blackwell Science, Oxford, pp 32.1–32.48Google Scholar
  15. Markle WH, Makhoul K (2004) Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician 69(6):1455–1464PubMedGoogle Scholar
  16. Mishra J, Carpenter S, Singh S (2010) Low serum zinc levels in an endemic area of visceral leishmaniasis in Bihar, India. Indian J Med Res 131(6):793PubMedGoogle Scholar
  17. Najim RA, Sharquie KE, Al-Zubaidy SAA (2006) Possible mechanisms of action of the compounds injected intralesionally in the treatment of cutaneous leishmaniasis, in addition to their direct effects on the parasites. Ann Trop Med Parasitol 100(1):33–38PubMedGoogle Scholar
  18. Norouzinezhad F, Ghaffari F, Norouzinejad A, Kaveh F, Gouya MM (2016) Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed 6(7):614–619Google Scholar
  19. Oslen RE, Berdanier CD (1994) Microminerals. In: Munson PH, Mueller RA, Breese GR (eds) Principles of pharmacology, 1st edn. Chapman & Hall, New York, pp 1002–1005Google Scholar
  20. Pardakhty A, Moazeni E, Varshosaz J, Hajhashemi VA, Najafabadi AR (2011) Pharmacokinetic study of niosome-loaded insulin in diabetic rats. DARU J Pharm Sci 19(6):404Google Scholar
  21. Pardakhty A, Shakibaie M, Daneshvar H, Khamesipour A, Mohammadi-Khorsand T, Forootanfar H (2012) Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. J Microencapsul 29(3):219–224PubMedGoogle Scholar
  22. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC et al (2003) Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 36(1):65–69PubMedGoogle Scholar
  23. Raimer S, Maloney JM, Bourcier M, Wilson D, Papp K, Siegfried E, Garrett S (2008) Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. Cutis 81(2):171–178PubMedGoogle Scholar
  24. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A (1998) Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–95. Bull World Health Organ 76(3):289PubMedPubMedCentralGoogle Scholar
  25. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ (2001) Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 26(1):21–26PubMedGoogle Scholar
  26. Sharquie KE, Noaimi AA, Sharara ZA, Saleh BA, Al-Salam WS (2017) Topical therapy of acute cutaneous leishmaniasis using zinc sulphate solution 25% versus podophyllin solution 25%. J Cosmet Dermatol Sci Appl 7(03):258Google Scholar
  27. Sorkhroodi FZ, Naeini AA, Ramazani AZ, Ghazvini MA, Mohebali M, Keshavarz SA (2010) Therapeutic effect of sodium selenite and zinc sulphate as supplementary with meglumine antimoniate (glucantime®) against cutaneous leishmaniasis in BALB/c mice. Iran J Parasitol 5(3):11PubMedPubMedCentralGoogle Scholar
  28. Yasinzai M, Khan M, Nadhman A, Shahnaz G (2013) Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. Future Med Chem 5(15):1877–1888PubMedGoogle Scholar
  29. Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, Yousefzadeh H (2011) Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatol Res Pract 2011:269515PubMedPubMedCentralGoogle Scholar
  30. Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45(3):420–434PubMedGoogle Scholar

Copyright information

© Indian Society for Parasitology 2018

Authors and Affiliations

  • Saeedeh Farajzadeh
    • 1
  • Rahim Ahmadi
    • 2
  • Saman Mohammadi
    • 1
  • Abbas Pardakhty
    • 3
  • Maryam Khalili
    • 1
  • Mahin Aflatoonian
    • 1
    Email author
  1. 1.Leishmaniasis Research Center, Afzalipour HospitalKerman University of Medical SciencesKermanIran
  2. 2.Dermatology Department, Afzalipour HospitalKerman University of Medical SciencesKermanIran
  3. 3.Pharmaceutics Research Center, Neuropharmacology InstituteKerman University of Medical SciencesKermanIran

Personalised recommendations